


Sciadopitysin

Cat. No.:	HY-N2119
CAS No.:	521-34-6
Molecular Formula:	C ₃₃ H ₂₄ O ₁₀
Molecular Weight:	580.54
Target:	NF-κB; TNF Receptor
Pathway:	NF-κB; Apoptosis
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 20 mg/mL (34.45 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass			
			1 mg	5 mg	10 mg	
			1 mM	1.7225 mL	8.6127 mL	17.2253 mL
			5 mM	0.3445 mL	1.7225 mL	3.4451 mL
10 mM	0.1723 mL	0.8613 mL	1.7225 mL			
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2 mg/mL (3.45 mM); Suspended solution; Need ultrasonic					

BIOLOGICAL ACTIVITY

Description	Sciadopitysin is a type of biflavonoids in leaves from ginkgo biloba ^[1] . Sciadopitysin inhibits RANKL-induced osteoclastogenesis and bone loss by inhibiting NF-κB activation and reducing the expression of c-Fos and NFATc1 ^[2] .
IC ₅₀ & Target	NF-κB
In Vitro	Sciadopitysin (2.5, 5, 10 μM) strongly reduces RANKL-induced osteoclast-specific genes expression, including cathepsin K (CTSK), tartrate-resistant acid phosphatase (TRAP) and MMP-9. Furthermore, Sciadopitysin apparently attenuates RANKL-increased expressions of c-Fos and NFATc1 ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Sciadopitysin (i.p.; 10 mg/kg; every other day for 8 days) can reverse the bone loss in LPS-induced mice model (C57BL/6 mice; 6 weeks old) ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Arch Pharm (Weinheim). 2024 May 29:e2400066.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Briançon-Scheid F, et al. HPLC Separation and Quantitative Determination of Biflavones in Leaves from Ginkgo biloba. *Planta Med.* 1983 Dec;49(12):204-7.
- [2]. Sciadopitysin suppresses RANKL-mediated osteoclastogenesis and prevents bone loss in LPS-treated mice. *Int Immunopharmacol.* 2017 Aug;49:109-117.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA